These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26850490)

  • 21. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
    Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA
    J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
    Friedberg JW
    Chin Clin Oncol; 2015 Mar; 4(1):9. PubMed ID: 25841716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
    Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
    Riedell PA; Smith SM
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):91-97. PubMed ID: 29352717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral immune cell profiling of double-hit lymphoma by mass cytometry.
    Lei T; Wu G; Xu Y; Zhuang W; Lu J; Han S; Zhuang Y; Dong X; Yang H
    BMC Cancer; 2023 Feb; 23(1):184. PubMed ID: 36823603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
    Gordon MJ; Westin JR
    Leuk Lymphoma; 2022 May; 63(5):1034-1044. PubMed ID: 34842019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
    Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
    Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
    Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
    Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW
    Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
    Al-Juhaishi T; Wang Y; Milton DR; Xu-Monette ZY; Jabbour E; Daher M; Im JS; Bashir Q; Iyer SP; Marin D; Olson AL; Popat U; Qazilbash M; Rondon G; Gulbis AM; Champlin RE; Young KH; Khouri IF
    Bone Marrow Transplant; 2023 Sep; 58(9):1000-1007. PubMed ID: 37198234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.
    Lin P; Medeiros LJ
    Curr Hematol Malig Rep; 2013 Sep; 8(3):243-52. PubMed ID: 23892979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double hit and double expressors in lymphoma: Definition and treatment.
    Riedell PA; Smith SM
    Cancer; 2018 Dec; 124(24):4622-4632. PubMed ID: 30252929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
    Sarkozy C; Traverse-Glehen A; Coiffier B
    Lancet Oncol; 2015 Nov; 16(15):e555-e567. PubMed ID: 26545844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flow cytometry is of limited utility in the early identification of "double-hit" B-cell lymphomas.
    Platt MY; DeLelys ME; Preffer FI; Sohani AR
    Cytometry B Clin Cytom; 2013 May; 84(3):143-8. PubMed ID: 23341189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
    Petrich AM; Nabhan C; Smith SM
    Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.